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Sequencing and exome-chip technologies have motivated development of novel statistical tests to identify rare genetic variation that
influences complex diseases. Although many rare-variant association tests exist for case-control or cross-sectional studies, far fewer
methods exist for testing association in families. This is unfortunate, because cosegregation of rare variation and disease status in families
can amplify association signals for rare variants. Many researchers have begun sequencing (or genotyping via exome chips) familial sam-
ples that were either recently collected or previously collected for linkage studies. Because many linkage studies of complex diseases
sampled affected sibships, we propose a strategy for association testing of rare variants for use in this study design. The logic behind
our approach is that rare susceptibility variants should be found more often on regions shared identical by descent by affected sibling
pairs than on regions not shared identical by descent. We propose both burden and variance-component tests of rare variation that are
applicable to affected sibships of arbitrary size and that do not require genotype information from unaffected siblings or independent
controls. Our approaches are robust to population stratification and produce analytic p values, thereby enabling our approach to scale
easily to genome-wide studies of rare variation. We illustrate our methods by using simulated data and exome chip data from sibships
ascertained for hypertension collected as part of the Genetic Epidemiology Network of Arteriopathy (GENOA) study.Introduction
Many recent genetic studies of complex human traits have
been designed to determine the effects of rare or less-
common genetic variants on phenotype. These studies
have used either next-generation sequencing technology
(which enables complete interrogation of single-nucleo-
tide variants throughout the human genome) or cheaper
alternatives like the Illumina HumanExome Beadchip,
which provides genotypes for nearly 250,000 markers, pri-
marily protein-altering variants, that were identified from
large-scale resequencing efforts (details on the Beadchip
design available online; see Web Resources). These new
technologies have spurred the development of powerful
new statistical approaches for rare-variant association
testing of complex traits. However, the majority of such
tests are tailored for use in either case-control or popula-
tion-based studies that assume unrelated subjects. Fewer
rare-variant association tests exist for family-based studies,
which is unfortunate because families are uniquely suited
for studying rare variants.
Family-based studies of rare variants possess many valu-
able attributes that population studies lack. Rare suscepti-
bility variants are likely to be enriched in affected relatives
and therefore be easier to detect relative to population-
based counterparts.1,2 Family-based tests of rare-variant
association can also be made robust to population stratifi-
cation,3 which is important given recent work suggesting
that existing common-variant-based methods to correct
for stratification might not be as effective in studies of
rare variants.4,5 Several projects have initiated collection1Department of HumanGenetics, Emory University, Atlanta, GA 30322, USA; 2
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The Amof families for rare-variant analysis, including studies of
epilepsy6 and simplex autism.7 Additionally, other projects
have begun analysis of rare variants in familial samples
collected from past linkage studies. One such project is
the Genetic Epidemiology Network of Arteriopathy
(GENOA) study,8 which has genotyped a large collection
of African American sibships with hypertension for the
Illumina HumanExome Beadchip. Other linkage studies
were funded for rare-variant analysis via a NIH funding
opportunity titled ‘‘Life After Linkage: The Future of Family
Studies’’ (RFA-HL-12-007) that was sponsored by the
National Heart, Lung, and Blood Institute.
To fully capitalize on the opportunities presented by
sequencing family members originally recruited into link-
age studies, it is necessary to develop new statistical tools
for rare-variant analysis in such projects. Although several
rare-variant methods exist for family-based analysis, some
are entirely restricted to quantitative traits.9–12 Other fam-
ily-based tests for use in complex diseases3,13–15 require in-
formation from both affected and unaffected individuals
for inference. For the many linkage studies that collected
only affected sibs, there might not be data from unaffected
family members that can be used for inference. The use of
historical controls is unappealing because of potential bias
from population stratification4 as well as the need to
account for differences in sequencing coverage.16 Thus, a
statistical approach for rare-variant analysis in affected
sibships that is self-contained and that does not require in-
formation from unaffected subjects is appealing.
We propose a strategy for association testing of rare var-
iants in affected sibships that is motivated by the notionDepartment of Epidemiology, University ofMichigan, Ann Arbor, MI 48103,
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that, among affected sibling pairs, we would expect to
observe more copies of rare susceptibility variants on hap-
lotypes shared identical by descent by the pair than on
haplotypes not shared identical by descent. We can eval-
uate this hypothesis without knowledge of haplotype
phase by using an efficient-score test derived from an esti-
mating-equation model. In this model, we regress the
number of copies of rare variants an affected sib pair pos-
sesses on the number of loci they share that are identical
by descent. Many family-based studies already have iden-
tity by descent (IBD) information from earlier linkage
studies or GWASs but, if this is not the case, such informa-
tion can be obtained from sequence data or common SNPs
found on the Illumina HumanExome Beadchip. Although
our approach uses IBD information for association testing,
it is not a test of linkage and, as we will show, can detect
rare-variant association signals in regions that do not har-
bor a significant linkage signal.
With our framework, we derive both ‘‘linear’’ or
‘‘burden’’ tests, which collapse multiple rare variants
within a region of interest into a single composite variable
and then test for association between that variable and IBD
status,17–21 and ‘‘quadratic’’ or ‘‘variance-component’’ tests
that compare pairwise similarity in IBD status to genotypic
similarity within the sample.22,23 Adaptive procedures that
combine aspects of both the burden and variance-compo-
nent classes of tests are also possible24 but are not consid-
ered here. As we will show, our strategy is robust to
confounding as a result of population stratification and
can handle sibships of arbitrary size. Unlike existing rare-
variant tests of complex diseases in pedigrees, our
approach is tailored for analysis of datasets comprised
entirely of affected sibships. That is, the approach does
not require variant information from unaffected relatives,
although such information can be used to assist in esti-
mating IBD sharing among affected siblings. The test has
a closed form and p values can be obtained analytically,
which facilitates genome-wide analysis. In subsequent sec-
tions, we derive our rare-variant association test and illus-
trate the approach by using both simulated sequence
data as well as exome-chip data from affected sibships
collected by the GENOA study.Materials and Methods
Assumptions and Notation
We assume we possess sequence or exome-chip data from a
collection of N affected sibships of arbitrary size. We assume sib-
ship j (j ¼ 1, ., N) is comprised of Mj affected siblings that can
be partitioned into Sj ¼ (Mj)(Mj  1) / 2 possible pairs. We consider
the analysis of a gene or region and let R denote the number of
polymorphic rare-variant sites observed in the gene or region
(with a rare variant defined as a variant whose frequency is less
than some threshold value, such as 0.01 or 0.05). We define Tij
as the total number of copies of rare variants at the R sites
possessed by the ith sib pair in the jth sibship. If desired, we can
up- or down-weigh the contributions of specific rare variants544 The American Journal of Human Genetics 96, 543–554, April 2, 2over others in the Tij count by applying site-specific weights
using information such as minor-allele frequency19,22 or func-
tional information;21 in this case, Tij denotes the weighted sum.
We further define Zij as the estimated number of copies of the
gene/region shared identical by descent by the ith sib pair in the
jth sibship, which we can infer via the Lander-Green25 algorithm
(or an extension that allows for linkage disequilibrium among
markers26), as implemented in software packages like MERLIN.27Proposed Model
Our model assumes the mean and variance in the number of
copies of rare causal variants on haplotypes inherited by an
affected sibling pair differ depending on whether the haplotype
is inherited identical by descent or not. We define the mean and
variance of the number (or weighted sum) of rare variants on a
parental haplotype inherited identical by descent as m1 and s
2
1,
respectively. Similarly, we define m0 and s
2
0 as the mean and vari-
ance of the number (or weighted sum) of rare variants on a
parental haplotype that is not inherited identical by descent by
the affected pair. If a sib pair shares zero haplotypes identical by
descent, then the pair possess two independent maternal haplo-
types that are not shared identical by descent and two indepen-
dent paternal haplotypes that are not shared identical by descent.
If a sib pair shares one haplotype identical by descent, then the
pair possesses two identical haplotypes (shared identical by
descent) inherited from one parent and two distinct independent
haplotypes (not shared identical by descent) inherited from the
other parent. If the pair shares two haplotypes identical by
descent, then the pair possesses two identical maternal haplotypes
(shared identical by descent) and two identical paternal haplo-
types (shared identical by descent). Based on this information,
we can derive the mean and variance of Tij conditional on the
IBD sharing Zij as
E

Tij jZij
 ¼
8<: 4m02m0 þ 2m1
4m1
Zij ¼ 0
Zij ¼ 1
Zij ¼ 2
(Equation 1)
and
Var

Tij jZij
 ¼
8<: 4s
2
0
2s20 þ 4s21
8s21
Zij ¼ 0
Zij ¼ 1
Zij ¼ 2:
(Equation 2)
Our primary interest is to test the null hypothesis that H0:
m0 ¼ m1. To simplify presentation, we reparameterize our model
by defining d ¼ m1  m0 so that we can rewrite Equation 1 as
E

Tij jZij
 ¼ 4m0 þ 2dZij (Equation 3)
and reconfigure our primary null hypothesis to be H0: d ¼ 0. Based
on Equations 2 and 3, we can perform inference on the parameter
d by solving the following estimating equations for (m0, d):
XN
j¼1
XSj
i¼1
Wij

Tij  4m0  2dZij
 4
2Zij

¼

0
0

(Equation 4)
whereWij¼ (Var(TijjZij))1.We are primarily interested in a 1-sided
test of H0: d ¼ 0 versus HA: d > 0 because, given the non-random
ascertainment of affected sibships, we anticipate rare risk variants
to be observed on segments shared identical by descent. However,
we can also perform the standard 2-sided test of H0: d ¼ 0 versus
HA: ds 0, if desired, to allow for the possibility of rare protective
variants observed in regions not shared identical by descent by an015
affected sib pair. We note that analysis via Equation 4 is robust to
confounding due to population stratification because, although
ancestry might correlate with the number of copies of rare variants
in a region, ancestry will not correlate with IBD sharing in a region
under the null hypothesis that the genetic variation we are testing
is neither causal nor in linkage disequilibrium with other causal
regions.
Inference on d within Equation 4 requires estimates of the vari-
ance parameters s20 and s
2
1 shown in Equation 2. To estimate these
parameters, we first calculate the sample variance for the number
(or weighted sum) of rare variants possessed by affected sib pairs
sharing 0, 1, or 2 alleles identical by descent and denote these
quantities by bV 0; bV 1, and bV 2, respectively. Based on Equation 2,
we can then estimate the variance parameters by solving the sys-
tem of equations 24 bV 0bV 1bV 2
35 ¼
244 02 4
0 8
35s20
s21
	
:
Defining bV ¼ ð bV 0; bV 1; bV 2ÞT and X ¼
244 02 4
0 8
35, we then estimate
the variance parameters as
 bs20bs21
	
¼ ðXTXÞ1XT bV . We then use
these estimates to define Wij in Equation 4. If IBD state is known
only probabilistically, we assign each sib pair to its most probable
IBD state when calculating bV ¼ ð bV 0; bV 1; bV 2ÞT .
In the formulation of Equation 4, we assumed that we inferred
the IBD sharing variable Zij with certainty. Although this assump-
tion probably holds when inferring IBD information from
sequence data, the use of sparser SNP sets from the exome
chip for estimation might lead to IBD uncertainty. In this
case, we specify Zij as the expected IBD dosage by using
Zij ¼ bP½Zij ¼ 1 þ 2bP½Zij ¼ 2, where the estimated IBDprobabilities
are calculated by MERLIN.27 We can insert such IBD dosage vari-
ables directly into the mean model in Equation 3. To modelWij ¼
(Var(TijjZij))1 for a pair with uncertain IBD sharing, we assign the
IBD state to be the most-likely IBD sharing category. Although
this leads to misspecification of Var(TijjZij), we note that such mis-
specificationdoesnot affect thevalidity of our estimation-equation
testing framework and only potentially affects the power.
Efficient Score Function and Test Statistics
Rather than solve a system of two equations (Equation 4), we can
instead simplify the problem by finding the efficient score for
d from the weighted regression of Tij on Zij. After first normalizing
the weightsWij, we define the centered count and IBD variables as
~Tij ¼ Tij 
PN
j¼1
PSj
i¼1WijTij and ~Zij ¼ Zij 
PN
j¼1
PSj
i¼1WijZij, respec-
tively. As we show in Appendix A, the efficient score to test H0:
d ¼ 0 based on Equation 4 is proportional to
U ¼
XN
j¼1
XSj
i¼1
Wij ~Tij~Zij ¼
XN
j¼1
XSj
i¼1
Uij: (Equation 5)
To construct the estimated variance accounting for within-
sibship correlation of sib pairs, we use a robust variance estimator
that accounts for cluster membership.28 This variance estimator
has the form
V ¼
XN
j¼1
(XSj
i¼1
Wij ~Tij~Zij
)2
 N
U
N
2
: (Equation 6)The AmWith Equations 5 and 6, we can then construct a closed-form
burden test to assess H0: d ¼ 0 by writing
YBurden ¼ UﬃﬃﬃﬃVp :
Under H0: d ¼ 0, YBurden follows a standard normal distribution.
In addition to a burden test, we can also consider a variance-
component test of rare-variant association analogous to SKAT.22
The approach assumes that d follows a random effect with
mean 0 and variance t and then considers a score test of H0:
t ¼ 0. Such a variance-component test might be preferable to
the burden test YBurden if we expect, in addition to rare susceptibil-
ity variants in regions shared identical by descent, the possibility
that a region might harbor rare protective variants on regions
not shared identical by descent by an affected sib pair. We can
use the efficient score framework to construct such a test by sum-
ming the squared contribution of the efficient score function at
each variant site. By definition, Tij ¼
PR
r¼1Tijr , where Tijr denotes
the total number of rare variants possessed at variant site r
(r ¼ 1, ., R) by sib pair i in sibship j. Because R is fixed and rare
variants typically exhibit low linkage disequilibrium, we expect
VarðTijr
ZijÞzð1=RÞVarðTijZijÞ, suggesting that we choose Wijr ¼
Wij as calculated previously, because the weights we use are
normalized. Similar to Equation 6, we can define Uijr ¼ Wij ~Tijr ~Zij
and then define our variance-component test statistic as
YVC ¼
XR
r¼1
(XN
j¼1
XSj
i¼1
Uijr
)2
:
Under the null hypothesis, YVC follows amixture of chi-square dis-
tributions29
P
rlrc
2
1 where the l parameters denote the eigen-
values of the R by Rmatrix S, where row r and column r’ element
of the matrix has the form
Sr;r0 ¼
XN
j¼1
(XSj
i¼1
UijrUijr0
)
 1
N
(XN
j¼1
XSj
i¼1
Uijr
)(XN
j¼1
XSj
i¼1
Uijr0
)
:
As before, this variance estimator accounts for within-sibship
correlation.28 We can analytically calculate the p value of YVC
via Davies method.30
Application to Simulated Datasets
We evaluated the size and power of our test for rare-variant associ-
ation testing in sibships by using simulated sequence data. With
COSI,31 we generated 10,000 haplotypes of length 10 kb whose
variation patterns emulated those observed in HapMap CEU
(Utah residents with ancestry from northern and western Europe
from the CEPH collection) samples. To generate data with con-
founding by population stratification, we similarly simulated
10,000 haplotypes whose variation patterns mimicked those
observed in HapMap YRI (Yoruba in Ibadan, Nigeria) samples.
For each population sample, we generated sequence data for a sib-
ship by first randomly sampling two haplotypes for each parent:
parents were either both European for simulations without con-
founding, or both European or both African for simulations with
confounding. We then randomly transmitted one maternal and
one paternal haplotype to each offspring in a sibship, keeping
track of the inheritance flow in the family to derive pair-wise
IBD sharing among all pairs of siblings.
We then modeled the probability of disease for an index pro-
bandwithin a sibship by using a logistic function that has an inter-
cept, a term for African origin (for simulations with confounding),erican Journal of Human Genetics 96, 543–554, April 2, 2015 545
Table 1. Distribution of Sibship Size in GENOA Dataset
Sibship Size Count
1 (singleton) 204
2 226
3 101
4 53
5 23
6 8
7 6
8 2and an additive model for each risk variant (for models evaluating
power). For each simulation scenario, we chose the intercept to
yield an overall disease prevalence of 0.03. African origin increased
the odds of disease by a factor of 4 for simulations with confound-
ing. For power simulations, we assumed 15% of rare (minor allele
frequency [MAF] < 0.05) variants were causal with the magnitude
of the log odds ratio given by cjlog10(MAF)j, where we chose c to be
log(4)/4, log(6)/4, or log(8)/4, corresponding to a causal risk
variant with a MAF of 0.0001 having a disease odds ratio of 4, 6,
or 8, respectively. For some power simulations, we assumed that
all causal variants increased risk for disease. For other power simu-
lations, we assumed that half of causal variants increased risk and
the other half were protective and decreased risk. We then
randomly sampled the disease outcome for the index proband
and discarded the sibship if the index proband was unaffected.
Given that the index proband is affected, we then generated dis-
ease outcomes for each of the proband’s siblings assuming a total
sibship size of 2, 3, or 4 with the following model. Let y1 and y2
denote the disease status (y¼ 1 denotes affected) for the index pro-
band and an additional sibling, respectively. Further, define g1 and
g2 as the genotype vectors for rare susceptibility variants at the test
gene possessed by the index proband and additional sibling,
respectively. Also, let a be an indicator of African origin for the
two siblings. Wemust specify P(y2¼ 1jy1¼ 1,g1,g2,a); the probabil-
ity the additional sibling is affected conditional on the index pro-
band being affected and conditional on the rare-susceptibility
genotypes and ancestry of both siblings. To do this, we define
a conditional version of Risch’s sibling recurrence risk ratio32 as
lC ¼ P(y2 ¼ 1jy1 ¼ 1,g1,g2,a)/P(y2 ¼ 1jg1,g2,a), which models the
overall risk of disease due to shared sibling effects conditional on
the sibling’s ancestry and genotypes at the rare risk variants in
the gene of interest. We rewrite lC as a function of our probability
of interest as P(y2 ¼ 1jy1 ¼ 1,g1,g2,a) ¼ lCP(y2 ¼ 1jg1,g2,a). By
making the reasonable assumption that P(y2 ¼ 1jg1,g2,a) ¼
P(y2 ¼ 1jg2,a) (risk of disease of the additional sibling is indepen-
dent of the genotype information of the index proband
conditional on the additional sibling’s own genotype and the
ancestry of the sibship), our probability of interest simplifies to
P(y2¼ 1jy1¼ 1,g1,g2,a)¼ lCP(y2¼ 1jg2,a).We thenmodel this prob-
ability by varying the value of lC among values of 2, 4, and 8 (with
larger value indicating increased global risk of disease due to
shared sibling effects) and specifying P(y2 ¼ 1jg2,a) via the same
logistic function used to generate the disease phenotype for the
index proband. Data for each successive sib are sampled condi-
tional on the index proband but independently of the disease sta-
tus of subsequent sibs.546 The American Journal of Human Genetics 96, 543–554, April 2, 2With this model, we generated disease outcomes for 1, 2, or 3
successive sibs independently to obtain data for sibships of size
2, 3, or 4, respectively. We retained the sibship for analysis if the
resulting disease data satisfied the ascertainment criterion and dis-
carded the sibship otherwise. Our primary ascertainment criterion
was that the sibship possess at least two affected siblings but, for
sibships of size 3 and 4, we also considered a criterion requiring
three or more affected siblings for analysis. For a given simulation
model, we prospectively generated sequence and phenotype data
on sibships until we achieved a targeted number of sibships that
fulfilled the ascertainment criterion.
Application to GENOA Dataset
The GENOA study,8,33 which forms a component of the NHLBI
Family Blood Pressure Program,34 seeks to identify genetic variants
that influence risk for hypertension and arteriosclerotic/athero-
sclerotic complications involving the heart, brain, kidneys, and
peripheral arteries. As part of the study, GENOA ascertained a
cohort of African American sibs from Jackson, Mississippi, in
which R2 siblings had essential hypertension diagnosed prior to
the age of 60. 1,854 subjects were enrolled in the initial study
and approximately 80% were re-recruited for a second exam
many years later. Clinical data collected on such subjects include
essential hypertension status as well as quantitative and qualita-
tive outcomes related to lipid metabolism and organ function.
This study was approved by the institutional review boards at
the parent institutions of all participating laboratories involved
in GENOA.
The GENOA investigators genotyped 1,429 samples for 233,507
SNPs on the Illumina HumanExome Beadchip. After standard
data cleaning to remove problematic individuals and SNPs, the
final sample for analysis consisted of 1,392 participants in 623
sibships. We summarize the distribution of sibships in Table 1.
GENOA investigators used PLINK35 to estimate genome-wide
IBD sharing among relative pairs to confirm putative pedigree
structure. To infer site-specific IBD sharing in the GENOA sibships
for use in our proposed tests, we used 4,448 common autosomal
SNPs specifically included on the Illumina HumanExome Bead-
chip to infer inheritance flow. We identified the sex-averaged
linkage map position for each of these SNPs from the Rutgers
Map v.336 (see Web Resources). With this information, we first
used MERLIN27 to identify likely genotyping errors for the
4,448 SNPs in the GENOA families and subsequently set such
problematic genotypes to be missing. We then applied MERLIN
on the cleaned genotype data to infer IBD sharing among GENOA
family members at 1 centiMorgan (cM) intervals across the
autosomes.
With our rare-variant association test, we performed two sets of
analyses with affected siblings in GENOA.We first studied GENOA
affected siblings with essential hypertension (MIM 145500); pub-
lished sibling recurrence risk ratios for hypertension range be-
tween 1.5 and 3.5.37 We analyzed rare and less-common variants
(MAF % 0.05) found in a set of candidate genes containing com-
mon variation previously associated with blood pressure in inde-
pendent African American GWAS samples.38 We next focused on
GENOA affected siblings with obesity (MIM 601665); published
sibling recurrence risk ratios for obesity range between 2.6 and
4.2.39 We analyzed rare and less-common variants found in genes
harboring common variation previously associated with body-
mass index (BMI) in independent African American GWASs.40
For each set of analyses, we removed unaffected siblings prior
to association testing. We show the distribution of GENOA015
Table 2. Distribution of Affected Sibships in GENOA
Sibship Size
Count with
Hypertension
Count with
Obesity
2 204 183
3 75 68
4 35 26
5 12 9
6 4 1
7 0 1
8 1 1
Total Number of Pairs 847 697
Number of Pairs with Both
Hypertension and Obesity
484
Figure 1. Quantile-Quantile Plots of Observed p Values versus
Expected p Values on –log10 Scale for the YBurden and YVC Tests
under the Null Hypothesis for Samples of European Ancestry
Top left shows QQ plot for 500 sibships of size 2, top right shows
500 sibships of size 4, bottom left shows 1,000 sibships of size 2,
and bottom right shows 1,000 sibships of size 4. Each set of results
based on 10,000 replications with lC ¼ 4.affected sibships with the hypertension and obesity phenotypes in
Table 2. As shown in the table, there are a total of 847 affected sib-
ling pairs that are hypertensive and 697 affected sibling pairs that
are obese. Of these sib pairs, 484 overlap between the two datasets,
so that the proportion of hypertensive sib pairs that were also
obese was 0.57 while the proportion of obese sib pairs that were
also hypertensive was 0.69.
We identified the physical location of each tested gene from
the UCSC Genome Browser41 and included all variants on the
Illumina HumanExome Beadchip with MAF % 0.05 from 20 kb
upstream of the start of the gene position to 20 kb down-
stream beyond the end of the gene position. We found the corre-
sponding linkage map position (sex averaged) for each gene by
using Rutgers Map v.3 and extracted the IBD sharing of the
GENOA affected sibships at that position from our MERLIN
output. We considered both YBurden and YVC and performed
both unweighted analyses as well as more standard analyses
that weighted rare variants inversely proportional to their MAF
(using a weight corresponding to ð ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃMAFð1MAFÞp Þ1 as sug-
gested by others19).Simulations with Uncertainty in IBD Sharing
In the power simulations described previously, we assumed that
IBD sharing among affected sib pairs was known exactly when
constructing YBurden and YVC. By using next-generation
sequencing data, we would expect to infer IBD with near certainty.
However, for sparser data like the common SNPs found on the
Illumina HumanExome Beadchip, ambiguity in IBD sharing is a
possibility. To investigate the impact of IBD uncertainty on our
approaches, we looked at pairwise IBD estimates among affected
siblings in GENOA across the candidate genes that we explored
in this article. We provide a histogram of these estimates in
Figure S1. We repeated the simulations described previously but,
instead of using the true IBD sharing for each pair, we induced
ambiguity in IBD sharing by sampling from the distribution of
IBD estimates observed in the GENOA pairs. Specifically, if a pair’s
true IBD sharing was 0, we sampled the observed IBD sharing from
the distribution of GENOA IBD estimates between 0 and 0.5. If
true IBD sharing was 1, we sampled an observed IBD from GENOA
estimates between 0.5 and 1.5. Finally, if true IBD sharing was 2,
we sampled an observed IBD estimate from the GENOA estimates
between 1.5 and 2.The AmResults
Type I Error Results
We performed null simulations to ensure that YBurden and
YVC had appropriate size under different conditions.
Figure 1 shows quantile-quantile (QQ) plots for the
two tests in a situation where the sample consisted
entirely of subjects of European ancestry. The top half of
Figure 1 shows the QQ plots assuming a sample size of
500 sibships of size 2 (top left) or of size 4 (top right),
and the bottom half of Figure 1 shows QQ plots for
sample sizes of 1,000 sibships of size 2 (bottom left) or
of size 4 (bottom right). For each design, we analyzed
10,000 replicates of the data assuming lC ¼ 4 (we show
QQ plots under the same models when lC ¼ 8 in
Figure S2). The results show that both statistics have
appropriate type I error under the null and, based on
results that assumed sibships of size 4, appropriately
account for the dependency among observations due to
within-sibship correlation.
The type I error simulations shown in Figure 1 assumed
samples entirely of European ancestry (no confounding).
Figure 2 shows QQ plots for simulations with confound-
ing, assuming a sample size of 500 sibships of size 2 (top
left) or of size 4 (top right), or a sample size of 1,000 sib-
ships of size 2 (bottom left) or of size 4 (bottom right).
For each model, we analyzed 10,000 replicates of the
data assuming lC ¼ 4 (we provide QQ plots for lC ¼ 8 in
Figure S3). The results show that both tests are valid inerican Journal of Human Genetics 96, 543–554, April 2, 2015 547
Figure 2. Quantile-Quantile Plots of Observed p Values versus
Expected p Values on –log10 Scale for the YBurden and YVC Tests
under the Null Hypothesis with Samples of Both African and
European Ancestry
Odds ratio of disease for African versus European ancestry is 4. Top
left shows QQ plot for 500 sibships of size 2, top right shows 500
sibships of size 4, bottom left shows 1,000 sibships of size 2, and
bottom right shows 1,000 sibships of size 4. Each set of results
based on 10,000 replications with lC ¼ 4.
Figure 3. Power of YBurden and YVC Tests at a ¼ 2.5 x 106
Data were generated under a model where 15% of variants with
MAF % 0.05 were causal with effect on log(OR) of c,jlog10(MAF)j
(for risk variants) and c,jlog10(MAF)j (for protective variants).
Results are shown for c ¼ log(6)/4 and 500 sib pairs (top left), c ¼
log(6)/4 and 1,000 sib pairs (top right), c ¼ log(8)/4 and 500 sib
pairs (bottom left), and c ¼ log(8)/4 and 1,000 sib pairs (bottom
right). Each set of results based on 1,000 replications with lC ¼ 4.the presence of confounding resulting from population
stratification.
Power Results
In Figure 3 we compare the power of YBurden and YVC for
simulated data on affected sib pairs of European ancestry.
For all simulations we assumed lC¼ 4. Power wasmarkedly
higher for all tests when all causal alleles are risk alleles.
However, even when half the causal alleles are protective,
we observed that both the 1-sided and 2-sided YBurden
test outperformed YVC. This result is in contradistinction
to results showing that variance-component tests generally
outperform burden tests in case-control and cross-
sectional studies when the proportion of causal variation
is small.22 We believe the reason we observe this phenom-
enon is that the sampling of affected sibs implies the pres-
ence of cosegregating risk alleles in the family, which in
turn implies rare risk variants are shared identical by
descent. Protective variants preferentially found on haplo-
types not shared identical by descent would probably have
a smaller effect than risk variants for two reasons. First,
each sib already has enough risk alleles to cause disease.
Second, recall that haplotypes in affected sibships not
shared identical by descent are like untransmitted haplo-
types in a transmission-disequilibrium test; the distortion
of allele frequencies in untransmitted haplotypes is typi-
cally much smaller than that in transmitted haplotypes.
In a related finding, Jiang et al.42 observed burden tests548 The American Journal of Human Genetics 96, 543–554, April 2, 2to be more powerful than variance-component tests in
the study of case-parent trios, even when a gene harbored
an equal mixture of rare and protective variants. Based on
our findings, we recommend using the 1-sided YBurden test
as the primary analytic tool for rare-variant testing in
affected sibships.
We also performed simulations to compare the power of
our rare-variant association tests for affected sibships to the
power of a case-control study having the same sample size.
We assumed samples comprised ofM individuals that were
collected under one of three possible designs. First, we
generated sequence data prospectively under a case-con-
trol design assuming M/2 case subjects and M/2 control
subjects, and we analyzed the data via a logistic-regression
burden test that regressed disease status on the total num-
ber of rare variants possessed by a subject. Second, we
generated data on M/2 affected sib pairs and analyzed the
data via our 1-sided YBurden test. Finally, we generated
data on M/3 families, each having three affected sibs (sib
trios) and analyzed the data again with our 1-sided YBurden
test. Although ascertainment of siblings based on three or
more affected individuals is rare, we were curious to see
whether increasing the genetic load by requiring three
affected sibs would increase the power even as the number
of sibships decreased.
Figure 4 provides power comparisons at a ¼2.5 x 106
(corresponding to a Bonferroni correction for testing
20,000 independent genes) of case-control, affected sib
pair, and affected sib trio designs assuming 1,000 or
2,000 total sampling units. For all simulations, we used015
Figure 4. Power at a¼ 2.5 x 106 to Detect Rare Susceptibility Variants under Different Sampling Designs Assuming a Fixed Number
of M Sampling Units
Yellow bar denotes power using M/2 cases and M/2 controls using logistic-regression burden test. Green bar denotes power for M/2
affected sib pairs using 1-sided YBurden test. Blue bar denotes power forM/3 affected sib trios using 1-sided YBurden test. Results are shown
for c ¼ log(4)/4 (left column), c ¼ log(6)/4 (middle column), and c ¼ log(8)/4 (right column). Top row, lC ¼ 2; middle row, lC ¼ 4; bottom
row, lC ¼ 8. Each set of results based on 1,000 replications assuming 15% of rare variants are causal with 100% of causal variants
increasing risk.only samples of European ancestry and assumed that all
causal variants increased risk. We varied the value of lC
among the values of 2, 4, and 8 with corresponding power
results shown in the top, middle, and bottom panels of
Figure 4. In all scenarios, the results show that sampling
affected sibships is more powerful than the using a case-
control sample assuming the same number of sampling
units. Figure 4 also shows that the power of sib trios is
considerably higher than sib pairs, suggesting that more
stringent ascertainment criteria can improve the ability
to detect rare susceptibility variation. We should note
that the 1-sided YBurden test has appropriate size for
affected sib trios (see Figure S4). Further, when we repeated
the simulations summarized in Figure 4, using the
‘‘observed’’ IBD sharing estimated in the GENOA sibs in
place of the true IBD sharing, we observed negligible power
loss for our method, compared to using the true IBD for a
pair (see Figure S5).
Figure 4 also shows that the power of the 1-sided YBurden
test generally decreases with increasing value of lC. This
trend occurs because an increase in lC represents an in-
crease in the overall (polygenic) risk due to shared sibling
factors, not just the risk at the test locus. As lC increases,
the risk of disease increases even for sibs with no rare risk
variants in the gene of interest. Consequently, the propor-The Amtion of risk load carried by rare variation in a gene of inter-
est among affected sibships decreases as lC increases,
which leads to reduced power with the 1-sided YBurden
test. Nevertheless, even at sibling recurrence risk ratios of
8, the 1-sided YBurden test has equal or improved power
compared to the case-control design for a fixed sample size.
We also compared the power of rare-variant association
testing via the 1-sided YBurden test to the power of detecting
linkage at the same gene using the affected sibling pairs
generated to create Figure 4. We tested for linkage via a
minimax test43 assuming the IBD sharing of each affected
sib pair was known with certainty. We assumed the
genome-wide significance threshold for declaring linkage
suggested by Lander and Kruglyak.44 In Figure 5, we
compare the power to detect linkage to the power to detect
association assuming an appropriate genome-wide signifi-
cance threshold for both approaches, using our simulated
datasets that assumed lC ¼ 4. The results clearly show
that the power to detect a genome-wide significant associ-
ation via the 1-sided YBurden test is greater than the corre-
sponding power to detect a genome-wide significant
linkage signal across simulation models. Further, although
we observed correlation between the p values of the link-
age and association tests, the correlation was imperfect
and we identified many instances where we observed aerican Journal of Human Genetics 96, 543–554, April 2, 2015 549
Figure 5. Power to Detect Linkage and
Power to Detect Association in Affected
Sib Pairs under Different Sampling De-
signs Assuming 500 or 1,000 Affected Sib
Pairs
Yellow bar denotes power to detect linkage
at genome-wide significance threshold of
105. Magenta bar denotes power to detect
association using YBurden at genome-wide
threshold of 2.5 3 106. Results shown
for c ¼ log(4)/4 (left), c ¼ log(6)/4 (middle),
and c ¼ log(8)/4 (right). Each set of
results based on 1,000 replications
assuming lC ¼ 4 and 15% of rare variants
are causal with 100% of causal variants
increasing risk.significant association signal in the absence of a linkage
signal. For example, among the simulated datasets
assuming c¼ log(6)/4 (middle bar plot in Figure 5), we esti-
mated that the Spearman rho coefficient between the link-
age and association p values was 0.30 for 500 affected sib
pairs, which indicates a significant (p < 0.0001) yet imper-
fect correlation. However, of the 294 replicates that yielded
an (unadjusted) linkage p value > 0.05 (indicating little or
no evidence of linkage), 40% yielded a genome-wide-sig-
nificant association signal via the 1-sided YBurden test.
These results demonstrate that our approach can detect
association between rare variants and IBD sharing in the
absence of a strong linkage signal.
Application to GENOA Study
We applied our approach to test whether rare variants in
previously identified candidate genes affected essential hy-
pertension or obesity in the GENOA affected sibs. Based on
our simulation findings, we used the 1-sided YBurden test as
our primary analysis tool. We list each gene analyzed in
Table 3 along with its corresponding p values derived
from a weighted (based on MAF) or unweighted 1-sided
YBurden test. We performed association testing of 5 genes
withhypertension and12 geneswith obesity (withnoover-
lap in the genes tested for each phenotype). We then
performed these 17 tests twice using both the weighted
and unweighted forms. Although the weighted and un-
weighted tests are likely to be correlated,we elected to apply
a Bonferroni adjustment for 34 tests that yielded a signifi-
cance threshold of a ¼ 0.05/34 ¼ 0.0015. Although we
observed no significant association between rare variants
in blood-pressure genes with essential hypertension, we
observed an interesting association between rare variants
in NRXN3 (MIM 600567) and obesity (unadjusted p ¼
0.0024, adjusted p ¼ 0.0816). The unweighted 1-sided
YBurden test for this gene was less interesting, because it
yielded an unadjusted p value of 0.043. Further, we did
not observe a corresponding linkage signal at the locus550 The American Journal of Human Genetics 96, 543–554, April 2, 2015(LOD score of 0 using the Kong and
Cox45 exponential model imple-
mented in MERLIN). Examination ofIBD sharing among affected sib pairs at the NRXN3
confirmed no evidence of linkage as the proportion of
affected sib pairs that shared 0, 1, and 2 alleles identical
by descent (rounded to nearest integer) was 27%, 51%,
and 22%, respectively (see Table 4). To determine why the
weighted YBurden test yielded an interesting association in
the absence of either a signal from the unweighted YBurden
test or the linkage test, we examined the average rare-
variant burden of affected sib pairs with IBD ¼ 0, 1, and 2.
As shown in Table 4, the average rare-variant burdens of
the IBD ¼ 0 and IBD ¼ 2 affected sib pairs were similar for
the unweighted analysis. However, the allele frequency
of the rare variants decreased monotonically as the IBD
state increases, so that for theweighted analysis, the average
burdenof the IBD¼2affected sibpairswas greater than that
in IBD¼ 1 pairs, which in turn was greater than that of the
IBD ¼ 0 affected sib pairs.
The limited number of interesting rare-variant findings
in the GENOA study might indicate inherent differences
between our simulated and real data examples. We don’t
believe these differences are due to the sibling recurrence
risk ratios assumed in the simulations because they
include published values reported for hypertension and
obesity (1.5–3.5 and 2.6–4.2, respectively37,39). We do
note there are two intrinsic differences between our simu-
lation design and the GENOA analyses. First, the GENOA
study provided Illumina HumanExome Beadchip data
whereas our simulations assumed sequence data. Thus,
it is possible that the issue might be that the true
causal variation in the candidate genes investigated in
the GENOA study are not well interrogated on the
HumanExome Beadchip and must be assayed by a
sequencing approach. Second, we note the sample size
of the GENOA study (865 affected subjects in 331 sibships
for studying hypertension; 740 affected subjects in 289
sibships for studying obesity) is smaller than the sample
sizes considered in our simulations, which could explain
some of the difference between the power we observed
Table 3. Rare-Variant Analysis in GENOA Affected Sibships
Outcome Gene
p Value
(Weighted)
p Value
(Unweighted)
Hypertension GOSR2 0.865 0.674
GUCY1A3 0.421 0.513
PLEKHG1 0.378 0.387
SH2B3 0.970 0.932
ULK4 0.834 0.578
Obesity ADCY3 0.799 0.671
BDNF 0.520 0.585
FTO 0.597 0.346
GNPDA2 0.636 0.451
KLHL32 0.442 0.254
MAP2K5 0.890 0.670
MC4R 0.142 0.191
NFE2L3 0.919 0.872
NRXN3 0.0024 0.043
SEC16B 0.739 0.632
SH2B1 0.393 0.305
QPCTL 0.382 0.232
p value for YBurden based on 1-sided test. Weights based on
ð ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃMAFð1MAFÞp Þ1.
Table 4. Rare-Variant Association Analysis of NRXN3 in GENOA
Study
IBD State
Number
(Proportion)
of Affected
Sib Pairs
Average
Frequency of
Rare Variants
in NRXN3
Average Burden Per
Sib Pair
Unweighted Weighted
0 187 (0.27) .0070 0.043 0.820
1 354 (0.51) .0052 0.080 1.568
2 156 (0.22) .0024 0.067 2.310
IBD state of each affected sibling pair rounded to nearest integer value. Rare
variants are those with sample MAF < 0.05. Weighted analysis applied weight
based on ð ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃMAFð1MAFÞp Þ1.in our simulations and the results of our analyses of the
GENOA data.Discussion
As interest grows in sequencing or genotyping exome
chips on familial samples (such as those collected previ-
ously for linkage analysis), novel statistical procedures
that permit rare-variant association testing for these
studies are necessary. In this work, we proposed a rare-
variant association test for affected sibships of arbitrary
size that examines the relationship between the distribu-
tion of rare variants in a gene and the number of genes
shared identical by descent among affected sib pairs.
With simulations, we showed that rare-variant testing in
affected sibships is more powerful than a case-control
study with the same sample size, thereby illustrating the
strengths of family-based data for rare-variant association
analysis. Our method also possesses additional practical
features: it does not use any information from control sam-
ples; it is robust to confounding due to population stratifi-
cation; and our test statistics have simple closed forms with
analytic p values, making use of our approach straightfor-
ward via standard software packages (seeWeb Resources for
R code implementing our approach). Further, we have
shown that our methods perform well even when there
is uncertainty in IBD estimates from sparse SNP sets. We
illustrated the approach with an application to exomeThe Amchip data from the GENOA study in efforts to identify
genes harboring rare variation that increase risk for essen-
tial hypertension and obesity and identified a gene
(NRXN3) that might warrant further study for association
with obesity.
Although our rare-variant association test is based on
IBD sharing in affected sibling pairs, it is not a test of link-
age and does not require the presence of a linkage signal to
detect association (as demonstrated in the Results section
and in Figure 5). Linkage tests treat IBD sharing as the
outcome variable and looks for regions where estimated
IBD sharing across affected pairs deviate from their ex-
pected values based only on familial relationships. Our
proposed association test compares patterns of rare varia-
tion in a gene conditional on the IBD sharing in a region.
If linkage exists but there is no difference in rare-variation
patterns between regions shared identical by descent and
not shared identical by descent, then our proposed test
will not find a significant result. Conversely, our approach
can detect a significant association if the patterns of rare
variation differ between haplotypes that are and are not
shared identical by descent, even if there is no excess IBD
sharing as would be expected under linkage.
Our approach is tailored for rare-variant analysis in
affected sib pairs within sibships. In theory, we could
expand our approach to incorporate discordant sib pairs
in sibships where one sib is affected and the other sib is un-
affected. For such discordant sib pairs, we would expect to
find more rare susceptibility variants found on regions not
shared identical by descent than on regions shared iden-
tical by descent. We can modify our framework in Equa-
tion 4 to detect such patterns by incorporating the
expected sign of d (positive for affected sib pairs, negative
for discordant sib pairs) into the analysis. However, when
we performed preliminary power simulations to investi-
gate the potential utility of incorporating discordant pairs
into analysis, we found that such discordant units pro-
vided meager power (slightly more than the empirical
size) to identify regions harboring rare susceptibility vari-
ants unless the proportion of causal variants and their asso-
ciated effect sizes were unreasonably large (results not
shown). In fact, this is related to our finding that our vari-
ance components test was always less powerful than theerican Journal of Human Genetics 96, 543–554, April 2, 2015 551
two-sided burden test even when half of the causal alleles
were protective. Consequently, although we can use ge-
netic information on unaffected sibs to improve the accu-
racy of IBD estimation in affected sib pairs, we do not
recommend incorporating their information directly into
our rare-variant testing framework.
As we demonstrated in our simulations, our burden and
variance-component tests follow known asymptotic distri-
butions to facilitate genome-wide analysis. If desired,
we can also use resampling procedures to derive p values
for such tests; such procedures are probably valuable
when analyzing small samples. Because we assume an un-
derlying linear model in Equation 4, we can implement a
resampling procedure via a nonparametric bootstrap
approach46 that resamples residuals from the regression
analysis in Equation 4. This can be easily accomplished,
for example, in the R programming language. Formultiplex
sibships we should resample in a way that preserves the
within-sibship correlation, i.e., by resampling residuals
from a single sibship. With care, this can be done with
residuals fromsibships at least as large as theoneweare sam-
pling; for example, we can resample data for a sibship of size
3 by using residuals from a sibship of size 5, as long as we
choose (any) three sibs from that sibship and then select
the residuals that correspond to their (three) pairings.
Our regression framework in Equation 4 extends easily to
allow for modeling covariates at the pair level. Although
adjusting for potential covariates in non-randomly ascer-
tained samples is controversial,47–49 there might be value
in such adjustment, especially to untangle the effects of
rare variants from known common variants in a gene.50
To perform this adjustment, we create a variable for each
sib pair that counts the number of copies of theminor allele
of the common variant possessed by the pair, and we
include this count as a covariate in our model. We plan to
explore the value of such adjustment more in future work.
Our simulations show that using affected sib trios is even
more powerful than using affected sib pairs, even when the
sample size is held fixed. Although ascertaining families
based on three affected subjects is rare, some studies do
employ this strategy when collecting extended pedi-
grees.6,51 This motivates an extension of our approach to
handle data comprised of affected relative pairs of arbitrary
relatedness (e.g., first cousins, avuncular). For each type of
affected relative pair (e.g., affected first cousins), we can
implement the same framework discussed earlier by con-
structing an efficient score function that compares rare
variant count to IBD sharing across the pairs. To combine
results across different types of affected relative pairs
(e.g., a sample comprised of a mixture of affected sibling
pairs and affected first-cousin pairs), we can still use our
efficient score framework but require a separate intercept
parameter for each type of affected relative pair (to control
for differences in genotypic correlation between different
types of relative pairs). We are unsure whether an analysis
based on these distant affected pairs will be more powerful
than using case-control data, because second-order (and552 The American Journal of Human Genetics 96, 543–554, April 2, 2higher-order) relatives can share at most only one haplo-
type identical by descent (with the majority possessing
IBD ¼ 0). We intend to explore this in more detail in an
additional manuscript.Appendix A
Deriving the Efficient Score Function in Equation 5
from Estimating Equations in Equation 4
Given the estimating equations in Equation 4, define
Umðm0; dÞ ¼ 4
XN
j¼1
XSj
i¼1
Wij

Tij  4m0  2dZij

;
Udðm0; dÞ ¼ 2
XN
j¼1
XSj
i¼1
Wij

Tij  4m0  2dZij

Zij;
Hmmðm0; dÞ ¼
vUm
vm0
ðm0; dÞ ¼ 16
XN
j¼1
XSj
i¼1
Wij
Hmdðm0; dÞ ¼
vUm
vd
ðm0; dÞ ¼ 8
XN
j¼1
XSj
i¼1
WijZij
Then the efficient score for d is defined as
Ueffd ðdÞ ¼ Udðbm0ðdÞ; dÞ  Hmdðbm0ðdÞ; dÞHmmðbm0ðdÞ; dÞUmðbm0ðdÞ; dÞ
where bm0ðdÞ is the value of m0 that solves Um(m0,d) ¼ 0 (as a
function of d). Assuming the weightsWij are normalized, it
is straightforward to show that bm0ðdÞ ¼ ðPNj¼1PSji¼1WijðTij
2dZijÞÞ=4. Hence, we find
Ueffd ðdÞ ¼ 2
XN
j¼1
XSj
i¼1
Wij

~Tij  2d~Zij

~Zij;
where ~Tij and ~Zij are as defined in Equation 5. Dropping
the superfluous factor of 2, we thus conclude that U given
in Equation 5 is proportional to U
eff
d ðd ¼ 0Þ, the efficient
score for d at d ¼ 0. A simple interpretation of the efficient
score when estimating functions derived from a likelihood
is that the efficient score is the derivative of the profile
likelihood.Supplemental Data
Supplemental Data include five figures and can be found with this
article online at http://dx.doi.org/10.1016/j.ajhg.2015.01.020.Acknowledgments
We thank Dr. Karen Conneely and two anonymous reviewers for
their constructive comments related to this work. This work was
supported by HG007508 from the National Human Genome
Research Institute. GENOA is supported by HL086694 and
HL119443 from the National Heart, Lung, and Blood Institute.015
This manuscript has been reviewed by GENOA investigators for
scientific content and consistency of data interpretation with pre-
vious GENOA publications and significant comments have been
incorporated prior to submission for publication. M.P.E. is a
consultant for Amnion Laboratories. The findings and conclusions
in this article are those of the authors and do not necessarily repre-
sent the official position of the Centers for Disease Control and
Prevention.
Received: October 8, 2014
Accepted: January 30, 2015
Published: March 19, 2015Web Resources
The URLs for data presented herein are as follows:
Epstein software, http://genetics.emory.edu/labs/epstein/software
Exome Chip Design, http://genome.sph.umich.edu/wiki/Exome_
Chip_Design
International HapMap Project, http://hapmap.ncbi.nlm.nih.gov/
OMIM, http://www.omim.org/
Rutgers Map v.3, http://compgen.rutgers.edu/download_maps.
shtmlReferences
1. Teng, J., and Risch, N. (1999). The relative power of family-
based and case-control designs for linkage disequilibrium
studies of complex human diseases. II. Individual genotyping.
Genome Res. 9, 234–241.
2. Zo¨llner, S. (2012). Sampling strategies for rare variant tests in
case-control studies. Eur. J. Hum. Genet. 20, 1085–1091.
3. Ionita-Laza, I., Lee, S., Makarov, V., Buxbaum, J.D., and Lin, X.
(2013). Family-based association tests for sequence data, and
comparisons with population-based association tests. Eur. J.
Hum. Genet. 21, 1158–1162.
4. Mathieson, I., and McVean, G. (2012). Differential confound-
ing of rare and common variants in spatially structured popu-
lations. Nat. Genet. 44, 243–246.
5. Liu, Q., Nicolae, D.L., and Chen, L.S. (2013). Marbled inflation
from population structure in gene-based association studies
with rare variants. Genet. Epidemiol. 37, 286–292.
6. Consortium, E.K.; Epi4K Consortium (2012). Epi4K: gene dis-
covery in 4,000 genomes. Epilepsia 53, 1457–1467.
7. Krumm, N., O’Roak, B.J., Karakoc, E., Mohajeri, K., Nelson, B.,
Vives, L., Jacquemont, S., Munson, J., Bernier, R., and Eichler,
E.E. (2013). Transmission disequilibrium of small CNVs in
simplex autism. Am. J. Hum. Genet. 93, 595–606.
8. Daniels, P.R., Kardia, S.L., Hanis, C.L., Brown, C.A., Hutchin-
son, R., Boerwinkle, E., and Turner, S.T.; Genetic Epidemiology
Network of Arteriopathy study (2004). Familial aggregation of
hypertension treatment and control in the Genetic Epidemi-
ology Network of Arteriopathy (GENOA) study. Am. J. Med.
116, 676–681.
9. Chen, H., Meigs, J.B., and Dupuis, J. (2013). Sequence kernel
association test for quantitative traits in family samples.
Genet. Epidemiol. 37, 196–204.
10. Jiang, D., and McPeek, M.S. (2014). Robust rare variant associ-
ation testing for quantitative traits in samples with related in-
dividuals. Genet. Epidemiol. 38, 10–20.The Am11. Fang, S., Sha, Q., and Zhang, S. (2012). Two adaptive weight-
ing methods to test for rare variant associations in family-
based designs. Genet. Epidemiol. 36, 499–507.
12. Jiang, Y., Conneely, K.N., and Epstein, M.P. (2014). Flexible
and robust methods for rare-variant testing of quantitative
traits in trios and nuclear families. Genet. Epidemiol. 38,
542–551.
13. Schaid, D.J., McDonnell, S.K., Sinnwell, J.P., and Thibodeau,
S.N. (2013). Multiple genetic variant association testing by
collapsing and kernel methods with pedigree or population
structured data. Genet. Epidemiol. 37, 409–418.
14. Zhu, Y., and Xiong, M. (2012). Family-based association
studies for next-generation sequencing. Am. J. Hum. Genet.
90, 1028–1045.
15. Perdry, H., Mu¨ller-Myhsok, B., and Clerget-Darpoux, F. (2012).
Using affected sib-pairs to uncover rare disease variants. Hum.
Hered. 74, 129–141.
16. Garner, C. (2011). Confounded by sequencing depth in asso-
ciation studies of rare alleles. Genet. Epidemiol. 35, 261–268.
17. Li, B., and Leal, S.M. (2008). Methods for detecting associa-
tions with rare variants for common diseases: application to
analysis of sequence data. Am. J. Hum. Genet. 83, 311–321.
18. Morris, A.P., and Zeggini, E. (2010). An evaluation of statistical
approaches to rare variant analysis in genetic association
studies. Genet. Epidemiol. 34, 188–193.
19. Madsen, B.E., and Browning, S.R. (2009). A groupwise associ-
ation test for rare mutations using a weighted sum statistic.
PLoS Genet. 5, e1000384.
20. Zawistowski, M., Gopalakrishnan, S., Ding, J., Li, Y., Grimm,
S., and Zo¨llner, S. (2010). Extending rare-variant testing strate-
gies: analysis of noncoding sequence and imputed genotypes.
Am. J. Hum. Genet. 87, 604–617.
21. Price, A.L., Kryukov, G.V., de Bakker, P.I., Purcell, S.M., Staples,
J., Wei, L.-J., and Sunyaev, S.R. (2010). Pooled association tests
for rare variants in exon-resequencing studies. Am. J. Hum.
Genet. 86, 832–838.
22. Wu, M.C., Lee, S., Cai, T., Li, Y., Boehnke, M., and Lin, X.
(2011). Rare-variant association testing for sequencing data
with the sequence kernel association test. Am. J. Hum. Genet.
89, 82–93.
23. Neale, B.M., Rivas, M.A., Voight, B.F., Altshuler, D., Devlin, B.,
Orho-Melander, M., Kathiresan, S., Purcell, S.M., Roeder, K.,
and Daly, M.J. (2011). Testing for an unusual distribution of
rare variants. PLoS Genet. 7, e1001322.
24. Lee, S., Emond, M.J., Bamshad, M.J., Barnes, K.C., Rieder, M.J.,
Nickerson, D.A., Christiani, D.C., Wurfel, M.M., and Lin, X.;
NHLBI GO Exome Sequencing Project—ESP Lung Project
Team (2012). Optimal unified approach for rare-variant associ-
ation testing with application to small-sample case-control
whole-exome sequencing studies. Am. J. Hum. Genet. 91,
224–237.
25. Lander, E.S., and Green, P. (1987). Construction of multilocus
genetic linkagemaps in humans. Proc. Natl. Acad. Sci. USA 84,
2363–2367.
26. Abecasis, G.R., and Wigginton, J.E. (2005). Handling marker-
marker linkage disequilibrium: pedigree analysis with clus-
tered markers. Am. J. Hum. Genet. 77, 754–767.
27. Abecasis, G.R., Cherny, S.S., Cookson, W.O., and Cardon, L.R.
(2002). Merlin—rapid analysis of dense genetic maps using
sparse gene flow trees. Nat. Genet. 30, 97–101.
28. Williams, R.L. (2000). A note on robust variance estimation
for cluster-correlated data. Biometrics 56, 645–646.erican Journal of Human Genetics 96, 543–554, April 2, 2015 553
29. Zhang, D., and Lin, X. (2003). Hypothesis testing in semipara-
metric additive mixed models. Biostatistics 4, 57–74.
30. Davies, R. (1980). Algorithm as 155: The distribution of a
linear combination of chi-2 random variables. J. R. Stat. Soc.
[Ser A] 29, 323–333.
31. Schaffner, S.F., Foo, C., Gabriel, S., Reich, D., Daly, M.J., and
Altshuler, D. (2005). Calibrating a coalescent simulation of hu-
mangenome sequencevariation.GenomeRes.15, 1576–1583.
32. Risch, N. (1990). Linkage strategies for genetically complex
traits. I. Multilocus models. Am. J. Hum. Genet. 46, 222–228.
33. Lange, L.A., Lange, E.M., Bielak, L.F., Langefeld, C.D., Kardia,
S.L., Royston, P., Turner, S.T., Sheedy, P.F., 2nd, Boerwinkle,
E., and Peyser, P.A. (2002). Autosomal genome-wide scan for
coronary artery calcification loci in sibships at high risk for hy-
pertension. Arterioscler. Thromb. Vasc. Biol. 22, 418–423.
34. Investigators, F.; FBPP Investigators (2002). Multi-center ge-
netic study of hypertension: The Family Blood Pressure Pro-
gram (FBPP). Hypertension 39, 3–9.
35. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
36. Matise, T.C., Chen, F., Chen,W., De La Vega, F.M., Hansen,M.,
He, C., Hyland, F.C., Kennedy, G.C., Kong, X., Murray, S.S.,
et al. (2007). A second-generation combined linkage physical
map of the human genome. Genome Res. 17, 1783–1786.
37. Ward, R. (1990). Familial aggregation and genetic epidemi-
ology of blood pressure. In Hypertension: Pathophysiology,
Diagnosis, and Management (New York: Raven Press),
pp. 81–100.
38. Franceschini, N., Fox, E., Zhang, Z., Edwards, T.L., Nalls, M.A.,
Sung, Y.J., Tayo, B.O., Sun, Y.V., Gottesman, O., Adeyemo, A.,
et al.; Asian Genetic Epidemiology Network Consortium
(2013). Genome-wide association analysis of blood-pressure
traits in African-ancestry individuals reveals common associ-
ated genes in African and non-African populations. Am. J.
Hum. Genet. 93, 545–554.
39. Allison, D.B., Faith, M.S., and Nathan, J.S. (1996). Risch’s
lambda values for human obesity. Int. J. Obes. Relat. Metab.
Disord. 20, 990–999.554 The American Journal of Human Genetics 96, 543–554, April 2, 240. Monda, K.L., Chen, G.K., Taylor, K.C., Palmer, C., Edwards,
T.L., Lange, L.A., Ng, M.C., Adeyemo, A.A., Allison, M.A.,
Bielak, L.F., et al.; NABEC Consortium; UKBEC Consortium;
BioBank Japan Project; AGEN Consortium (2013). A meta-
analysis identifies new loci associated with body mass
index in individuals of African ancestry. Nat. Genet. 45,
690–696.
41. Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle,
T.H., Zahler, A.M., and Haussler, D. (2002). The human
genome browser at UCSC. Genome Res. 12, 996–1006.
42. Jiang, Y., Satten, G.A., Han, Y., Epstein, M.P., Heinzen, E.L.,
Goldstein, D.B., and Allen, A.S. (2014). Utilizing population
controls in rare-variant case-parent association tests. Am. J.
Hum. Genet. 94, 845–853.
43. Whittemore, A.S., and Tu, I.P. (1998). Simple, robust linkage
tests for affected sibs. Am. J. Hum. Genet. 62, 1228–1242.
44. Lander, E., and Kruglyak, L. (1995). Genetic dissection of com-
plex traits: guidelines for interpreting and reporting linkage
results. Nat. Genet. 11, 241–247.
45. Kong, A., and Cox, N.J. (1997). Allele-sharing models: LOD
scores and accurate linkage tests. Am. J. Hum. Genet. 61,
1179–1188.
46. Fox, J. (2002). Bootstrapping regression models. An R and
S-PLUS Companion to Applied Regression: A Web Appendix
to the Book (Sage).
47. Kuo, C.L., and Feingold, E. (2010). What’s the best statistic for
a simple test of genetic association in a case-control study?
Genet. Epidemiol. 34, 246–253.
48. Mefford, J., and Witte, J.S. (2012). The covariate’s dilemma.
PLoS Genet. 8, e1003096.
49. Pirinen, M., Donnelly, P., and Spencer, C.C. (2012). Including
known covariates can reduce power to detect genetic effects in
case-control studies. Nat. Genet. 44, 848–851.
50. Huyghe, J.R., Jackson, A.U., Fogarty, M.P., Buchkovich, M.L.,
Stanca´kova´, A., Stringham, H.M., Sim, X., Yang, L., Fuchs-
berger, C., Cederberg, H., et al. (2013). Exome array analysis
identifies new loci and low-frequency variants influencing in-
sulin processing and secretion. Nat. Genet. 45, 197–201.
51. Ottman, R., Berenson, K., and Barker-Cummings, C. (2005).
Recruitment of families for genetic studies of epilepsy. Epilep-
sia 46, 290–297.015
